Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Return on Sales (2016 - 2025)

Historic Return on Sales for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to 0.86%.

  • China Pharma Holdings' Return on Sales rose 1500.0% to 0.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.79%, marking a year-over-year increase of 700.0%. This contributed to the annual value of 1.05% for FY2024, which is 6100.0% down from last year.
  • As of Q3 2025, China Pharma Holdings' Return on Sales stood at 0.86%, which was up 1500.0% from 0.52% recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Return on Sales registered a high of 0.24% during Q1 2023, and its lowest value of 1.55% during Q2 2024.
  • For the 5-year period, China Pharma Holdings' Return on Sales averaged around 0.61%, with its median value being 0.54% (2023).
  • Per our database at Business Quant, China Pharma Holdings' Return on Sales tumbled by -10100bps in 2024 and then surged by 10400bps in 2025.
  • Over the past 5 years, China Pharma Holdings' Return on Sales (Quarter) stood at 0.34% in 2021, then fell by -28bps to 0.43% in 2022, then tumbled by -32bps to 0.57% in 2023, then plummeted by -88bps to 1.08% in 2024, then increased by 20bps to 0.86% in 2025.
  • Its Return on Sales was 0.86% in Q3 2025, compared to 0.52% in Q2 2025 and 0.69% in Q1 2025.